Pancreatic CancerPOWR-PaCNCT07772258
Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer
A study testing Corsano CardioWatch and Prehab4Cancer Programme in people with Pancreatic Cancer and Pancreatic Neoplasms, run by Manchester University NHS Foundation Trust.
Trial summary
The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer, Pancreatic Neoplasms, Periampullary Carcinoma
- What is being tested?
- Corsano CardioWatch and Prehab4Cancer Programme
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 30 Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients aged 18 years or older.
- Able to provide informed consent.
- Able to use the study devices independently or with support from a carer.
- Approved for pancreatic cancer surgery, including patients undergoing surgery for:
- Pancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).
- Clinically stable and considered suitable to participate in the prehabilitation and rehabilitation programme.
- Owns a smartphone or tablet device
Who cannot join
- Unable or unwilling to provide informed consent.
- Lacks capacity to provide informed consent.
- Unstable angina pectoris.
- Recent myocardial infarction.
- Recent cerebrovascular accident (stroke).
- New cardiac arrhythmia.
Show all 10Show fewer
- Social, physical, mental health, or substance misuse issues that, in the opinion of the investigator, would jeopardise adherence to study procedures or study contact.
- No infrastructure for remote monitoring (no access to either mobile signal or Wi-Fi).
- Clinically unstable or likely to require hospital admission within the next 72 hours.
- Unable to use the study devices and no carer or support person is available to assist.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Perioperative Optimisation and Wearable Remote Monitoring of Pancreatic Cancer
The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions.
The main questions it aims to answer are:
Read more
Does a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway?
Researchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes.
Participants will:
Provide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support.
Wear a Corsano CardioWatch device to continuously monitor physiological and activity data.
Use home monitoring equipment, including weight scales and blood pressure monitoring devices.
Complete questionnaires and participant logs during prehabilitation and recovery.
Receive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival.
Optionally participate in a focus group to discuss their experiences of wearable-enabled care.
Read the detailed description
POWR-PaC (Perioperative Optimisation and Wearable Remote monitoring of Pancreatic Cancer) is a prospective, single-centre study evaluating the integration of wearable technologies into an established perioperative prehabilitation and rehabilitation pathway for patients undergoing pancreatic surgery. The study is being conducted at Manchester University NHS Foundation Trust in partnership with the Greater Manchester Prehab4Cancer programme.
Major pancreatic surgery is associated with substantial morbidity, prolonged recovery, and significant variation in patient outcomes. Although prehabilitation programmes have demonstrated benefits for physical fitness and surgical preparedness, there is limited evidence regarding the role of continuous physiological monitoring and remote assessment throughout the perioperative pathway. Wearable technologies may provide objective, longitudinal measures of activity, sleep, cardiovascular function, recovery trajectories, and treatment tolerance that are not routinely captured during standard care.
Participants enrolled in the intervention arm will be prescribed the targeted Greater Manchester Prehab4Cancer pathway and will additionally receive a wearable monitoring package consisting of a Corsano CardioWatch device and supporting home monitoring equipment. Physiological and behavioural measures collected by the wearable system may include physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, sleep-related metrics, and other device-derived indicators. Weight and blood pressure measurements will also be collected using home monitoring equipment where applicable.
Data collection will occur across the perioperative pathway, including the pre-operative prehabilitation period, inpatient surgical admission, and post-operative rehabilitation phase. Clinical, functional, physiological, and patient-reported outcome measures will be collected alongside routinely recorded healthcare data. The study will evaluate data completeness, participant adherence, acceptability of remote monitoring, and the potential relationship between wearable-derived metrics and clinical outcomes.
A matched historical control cohort will be identified from electronic health records at Manchester University NHS Foundation Trust. Control participants will have undergone pancreatic surgery and standard perioperative care without participation in the wearable-enabled pathway. Matching methods will be used to minimise baseline differences between groups and support comparative analyses of clinical outcomes.
The primary clinical evaluation will focus on post-operative morbidity within 30 and 90 days of surgery. Secondary analyses will assess measures including mortality, hospital utilisation, days alive and out of hospital, functional recovery, quality of life, and engagement with prehabilitation and rehabilitation services. Exploratory analyses will investigate whether longitudinal wearable data can provide early indicators of recovery status, post-operative complications, or treatment response.
The study also incorporates a mixed-methods evaluation of implementation. Participants, healthcare professionals, and exercise specialists may be invited to take part in qualitative focus groups to explore experiences of wearable-supported care, barriers and facilitators to adoption, usability of the technology, and opportunities for future pathway optimisation. Qualitative findings will be used to inform the future design, implementation, and scale-up of digitally enabled perioperative pathways within NHS surgical services.
The findings from POWR-PaC will provide evidence regarding the feasibility, acceptability, and potential clinical value of integrating wearable technologies into perioperative cancer care and will inform the development of larger effectiveness studies and future digitally enabled surgical pathways.
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Periampullary Carcinoma, Pancreatic Surgery, Perioperative Care
- Being tested
- Corsano CardioWatch, Prehab4Cancer Programme
- Keywords
- Pancreatic Cancer, Pancreatic Surgery, Perioperative Care, Rehabilitation, Prehabilitation, Exercise, Nutrition, Wearables, Remote Monitoring, Digital Health, Mobile Health, Recovery of Function, Patient Monitoring, Telemedicine, Surgical Oncology, PROMS, Electronic Devices
- Medical subject headings
- Pancreatic Neoplasms, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Corsano CardioWatchDevice
A wearable monitoring device used throughout the perioperative pathway to collect continuous physiological and activity data, including measures such as physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, and sleep-related metrics.
Prehab4Cancer ProgrammeBehavioural
A personalised prehabilitation and rehabilitation programme comprising exercise, nutritional support, and wellbeing support delivered before and after pancreatic surgery.
| Study group | Role | What they receive |
|---|---|---|
| Wearable-Enabled Prehabilitation and Rehabilitation | Experimental | Participants undergoing pancreatic surgery will receive the Greater Manchester Prehab4Cancer programme supported by wearable monitoring, home physiological monitoring, and remote follow-up throughout the perioperative pathway. Outcomes will be compared with a propensity-score-matched historical cohort identified from routine electronic health records. Receives: Device: Corsano CardioWatch; Behavioral: Prehab4Cancer Programme |
| Matched Historical Standard Care Cohort | No intervention | Historical patients who underwent pancreatic surgery and received standard perioperative care without wearable monitoring. Participants will be identified retrospectively from electronic health records and matched to intervention participants using propensity score methods based on demographic and clinical characteristics. No study intervention will be delivered. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-operative complications
Occurrence of post-operative complications following pancreatic surgery.
Measured: 30 and 90 days post-surgery
Secondary outcomes (6)
All-cause mortality
All-cause mortality post-surgery
Measured: 30, 90, 365 days post-surgery.
Days Alive and Out of Hospital (DAOH)
Number of days participants are alive and not admitted to hospital during the preoperative period (from enrolment to surgery) and during the postoperative recovery period. DAOH incorporates mortality, length of stay, and hospital readmissions into a single patient-centred outcome measure.
Measured: From enrolment to date of surgery (preoperative period); and from date of surgery to 30, 90, and 365 days post-operatively (postoperative period).
Length of Stay
Number of days spent in hospital during the index surgical admission following pancreatic resection.
Measured: From date of surgical resection to date of discharge from the index hospital admission, assessed up to 90 days post-surgery.
Completeness of Wearable Data Collected via Corsano CardioWatch
Percentage of expected physiological and activity data points (heart rate, SpO2, activity, sleep) successfully captured and transmitted, relative to the total expected monitoring period. Unit: percentage
Measured: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Participant Adherence to Wearable Device Wear Time
Percentage of prescribed daily wear/use time achieved by participants. Unit: percentage
Measured: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Technical Feasibility of Wearable Device Data Collection
Number of technical issues (device malfunction, connectivity failure, data transmission gaps) encountered with the Corsano CardioWatch. Unit: count
Measured: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2026
- Study start1 Oct 2026 (estimated)
- Primary completion31 Mar 2028 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Manchester University NHS Foundation Trust
- Sponsor type
- Other government
- Collaborators
- Medtronic
- Responsible party
- Sponsor
- Investigators
- Lukas Hughes-Noehrer, PhD, Principal investigator, Manchester University NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07772258
- Sponsor's protocol ID
- B02760
- Other IDs
- ERP-2025-14388
- Acronym
- POWR-PaC
- Status last verified
- Aug 2026
- First submitted
- 31 Jul 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data underlying the results reported in publications arising from this study may be shared in an anonymised form following completion of the study and publication of the primary results. Shared datasets may include demographic data, clinical characteristics, patient-reported outcome measures, wearable-derived physiological and activity data, and key outcome variables relevant to the published analyses. Data will be fully anonymised prior to sharing and no directly identifiable information will be released. Access will be subject to approval by Manchester University NHS Foundation Trust, compliance with applicable data sharing agreements, participant consent, UK GDPR, research governance requirements, and any relevant ethical approvals. Supporting documentation, including the study protocol, statistical analysis methods, and data dictionary, may also be made available where appropriate.
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Optimisation and Wearable Remote Monitoring of Pancreatic Cancer
- ClinicalTrials.gov ID
- NCT07772258
- Acronym / sponsor ID
- POWR-PaC / B02760
- Conditions
- Pancreatic Cancer, Pancreatic Neoplasms, Periampullary Carcinoma, Pancreatic Surgery, Perioperative Care
- Keywords
- Pancreatic Cancer, Pancreatic Surgery, Perioperative Care, Rehabilitation, Prehabilitation, Exercise, Nutrition, Wearables
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Manchester University NHS Foundation TrustOther government
- Collaborators
- Medtronic
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 31 Mar 2028 (estimated)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 19 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions.
The main questions it aims to answer are:
Does a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway?
Researchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes.
Participants will:
Provide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support.
Wear a Corsano CardioWatch device to continuously monitor physiological and activity data.
Use home monitoring equipment, including weight scales and blood pressure monitoring devices.
Complete questionnaires and participant logs during prehabilitation and recovery.
Receive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival.
Optionally participate in a focus group to discuss their experiences of wearable-enabled care.
Detailed description
POWR-PaC (Perioperative Optimisation and Wearable Remote monitoring of Pancreatic Cancer) is a prospective, single-centre study evaluating the integration of wearable technologies into an established perioperative prehabilitation and rehabilitation pathway for patients undergoing pancreatic surgery. The study is being conducted at Manchester University NHS Foundation Trust in partnership with the Greater Manchester Prehab4Cancer programme.
Major pancreatic surgery is associated with substantial morbidity, prolonged recovery, and significant variation in patient outcomes. Although prehabilitation programmes have demonstrated benefits for physical fitness and surgical preparedness, there is limited evidence regarding the role of continuous physiological monitoring and remote assessment throughout the perioperative pathway. Wearable technologies may provide objective, longitudinal measures of activity, sleep, cardiovascular function, recovery trajectories, and treatment tolerance that are not routinely captured during standard care.
Participants enrolled in the intervention arm will be prescribed the targeted Greater Manchester Prehab4Cancer pathway and will additionally receive a wearable monitoring package consisting of a Corsano CardioWatch device and supporting home monitoring equipment. Physiological and behavioural measures collected by the wearable system may include physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, sleep-related metrics, and other device-derived indicators. Weight and blood pressure measurements will also be collected using home monitoring equipment where applicable.
Data collection will occur across the perioperative pathway, including the pre-operative prehabilitation period, inpatient surgical admission, and post-operative rehabilitation phase. Clinical, functional, physiological, and patient-reported outcome measures will be collected alongside routinely recorded healthcare data. The study will evaluate data completeness, participant adherence, acceptability of remote monitoring, and the potential relationship between wearable-derived metrics and clinical outcomes.
A matched historical control cohort will be identified from electronic health records at Manchester University NHS Foundation Trust. Control participants will have undergone pancreatic surgery and standard perioperative care without participation in the wearable-enabled pathway. Matching methods will be used to minimise baseline differences between groups and support comparative analyses of clinical outcomes.
The primary clinical evaluation will focus on post-operative morbidity within 30 and 90 days of surgery. Secondary analyses will assess measures including mortality, hospital utilisation, days alive and out of hospital, functional recovery, quality of life, and engagement with prehabilitation and rehabilitation services. Exploratory analyses will investigate whether longitudinal wearable data can provide early indicators of recovery status, post-operative complications, or treatment response.
The study also incorporates a mixed-methods evaluation of implementation. Participants, healthcare professionals, and exercise specialists may be invited to take part in qualitative focus groups to explore experiences of wearable-supported care, barriers and facilitators to adoption, usability of the technology, and opportunities for future pathway optimisation. Qualitative findings will be used to inform the future design, implementation, and scale-up of digitally enabled perioperative pathways within NHS surgical services.
The findings from POWR-PaC will provide evidence regarding the feasibility, acceptability, and potential clinical value of integrating wearable technologies into perioperative cancer care and will inform the development of larger effectiveness studies and future digitally enabled surgical pathways.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Wearable-Enabled Prehabilitation and Rehabilitation | Experimental | Device: Corsano CardioWatch, Behavioral: Prehab4Cancer ProgrammeParticipants undergoing pancreatic surgery will receive the Greater Manchester Prehab4Cancer programme supported by wearable monitoring, home physiological monitoring, and remote follow-up throughout the perioperative pathway. Outcomes will be compared with a propensity-score-matched historical cohort identified from routine electronic health records. |
| Matched Historical Standard Care Cohort | No intervention | –Historical patients who underwent pancreatic surgery and received standard perioperative care without wearable monitoring. Participants will be identified retrospectively from electronic health records and matched to intervention participants using propensity score methods based on demographic and clinical characteristics. No study intervention will be delivered. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adult patients aged 18 years or older.
- Able to provide informed consent.
- Able to use the study devices independently or with support from a carer.
- Approved for pancreatic cancer surgery, including patients undergoing surgery for:
- Pancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).
Key exclusion criteria (10 listed)
- Unable or unwilling to provide informed consent.
- Lacks capacity to provide informed consent.
- Unstable angina pectoris.
- Recent myocardial infarction.
- Recent cerebrovascular accident (stroke).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Corsano CardioWatchA wearable monitoring device used throughout the perioperative pathway to collect continuous physiological and activity data, including measures such as physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, and sleep-related metrics. | Device | Wearable-Enabled Prehabilitation and Rehabilitation |
| Prehab4Cancer ProgrammeA personalised prehabilitation and rehabilitation programme comprising exercise, nutritional support, and wellbeing support delivered before and after pancreatic surgery. | Behavioural | Wearable-Enabled Prehabilitation and Rehabilitation |
Primary outcome
Post-operative complications
Time frame: 30 and 90 days post-surgery
Occurrence of post-operative complications following pancreatic surgery.
6 secondary outcomes
All-cause mortality
Time frame: 30, 90, 365 days post-surgery.
Days Alive and Out of Hospital (DAOH)
Time frame: From enrolment to date of surgery (preoperative period); and from date of surgery to 30, 90, and 365 days post-operatively (postoperative period).
Length of Stay
Time frame: From date of surgical resection to date of discharge from the index hospital admission, assessed up to 90 days post-surgery.
Completeness of Wearable Data Collected via Corsano CardioWatch
Time frame: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Participant Adherence to Wearable Device Wear Time
Time frame: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Technical Feasibility of Wearable Device Data Collection
Time frame: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Individual participant dataSharing planned: Yes. Individual participant data underlying the results reported in publications arising from this study may be shared in an anonymised form following completion of the study and publication of the primary results. Shared datasets may include demographic data, clinical characteristics, patient-reported outcome measures, wearable-derived physiological and activity data, and key outcome variables relevant to the published analyses. Data will be fully anonymised prior to sharing and no directly identifiable information will be released. Access will be subject to approval by Manchester University NHS Foundation Trust, compliance with applicable data sharing agreements, participant consent, UK GDPR, research governance requirements, and any relevant ethical approvals. Supporting documentation, including the study protocol, statistical analysis methods, and data dictionary, may also be made available where appropriate.
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lukas Hughes-Noehrer, PhD principal investigator
Manchester University NHS Foundation Trust
Questions about this trial
What is this clinical trial studying?
A study testing Corsano CardioWatch and Prehab4Cancer Programme in people with Pancreatic Cancer and Pancreatic Neoplasms, run by Manchester University NHS Foundation Trust.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lynne Webster (00441612764125, lynne.webster@mft.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-operative complications (time frame: 30 and 90 days post-surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.